Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma

Table 1

Common adverse events and recommended management for lenvatinib treatment.

Adverse events	CTCAE grade	CTCAE description	Management
Proteinuria	1	0.15–1.0 g/24 h	None
	2	>1.0–3.5 g/24 h	(i) Hold lenvatinib until proteinuria resolves to ≤2.0 g/24 h; (ii) Consider consult nephrology
	3	>3.5 g/24 h	(i) Hold lenvatinib until proteinuria resolves to ≤2.0 g/24 h; (ii) Referral to nephrology
	4	Nephrotic syndrome	(i) Discontinue lenvatinib permanently; (ii) Referral to nephrology

CTCAE, Common Terminology Criteria for Adverse Events; , gram; h, hours.